RET and thyroid gland carcinoma: Among all the patients with RET-altered thyroid cancers treated with selpercatinib in the trial (n=162), grade 3 or grade 4 treatment related AEs occurred in 28% and 2% respectively, most frequently hypertension (in 21% of patients) and increased cytolytic liver enzymes (increased alanine aminotransferase in 11% and asparte aminotransferase in 9%).